dpp 4 and glp 1 together Frontiers dpp-4_inhibitors [TUSOM | Pharmwiki]

The Incretin System: Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes

Table of Contents How MASLD Presents Beyond Traditional Risk Factors Why GLP1s Are Gaining Attention in Liver Disease Recognizing Lean Liver Disease in Clinical Practice Integrating GLP1s into a LiverFirst Treatment Strategy Evidence Summary: What the Data Suggest Practical Considerations for Clinicians How MASLD Presents Beyond Traditional Risk Factors MASLD encompasses a spectrum from simple steatosis to inflammatory and fibrotic disease (NASH)

The efficacy of iGlarLixi in patients 65 years of age has been shown to be comparable with that of younger counterparts, and it can be used as an adjunct to diet and exercise in adults for the treatment of T2D that is inadequately controlled on oral glucose-lowering agents, GLP-1 RA, or basal insulin

Holst (2007)